BASEL, Switzerland & FRANKFURT, Germany--(BUSINESS WIRE)--Nitec Pharma AG, an emerging specialty pharma company, today announces the signing of an agreement with PAZ GmbH for the exclusive worldwide rights to Tarenflurbil, PAZ’s anti-inflammatory drug, for the treatment of chronic inflammation and pain. The in-licensing of Tarenflurbil broadens Nitec’s pipeline and underscores the company’s ambition to become a significant player focused on treating unmet medical needs in chronic inflammation and pain. The financial terms of the deal were not disclosed.
